Burt's non-myeloablative MIST trial is currently in Phase III and treatment of this larger randomized patient population is currently underway:http://clinicaltrials.gov/ct2/show/NCT0 ... sis&rank=2
The fully myeloblative (BEAM) study run out of Fred Hutchinson in Seattle has already completed treatment of all phase II trial patients and is currently performing the follow-up monitoring of the patients that will be completed over the next several years. However, the phase III trial plans have already been submitted to the FDA for approval and the phase III patient treatment will begin likely sometime in 2014 (hopefully a little earlier if possible). The following is just the phase II description. The phase III description should be the same, except with a larger patient treatment population and randomization:http://clinicaltrials.gov/ct2/show/NCT0 ... tle&rank=1
BTW Shaight. . . Like yourself I also was thinking about these issues at the time I was making the decision to go for HSCT for my own MS in 2009. Unfortunately there wasn't as much available data at that time as there is today. With what is known now I still favor the myeloablative protocol "in general" for progressive cases. However, if one does not have the option available, as a progressive patient I still would jump at the chance to have the non-myeloablative protocol because it still has a far higher probability & efficacy compared to any other treatment currently available. However, since you are still RRMS and the transition from RR-to-SP doesn't happen overnight, I think you're likely going to be good with the non-myeloablative protocol. But even if you do fall into the the roughly 20-25% of patients that relapse (or show lesion activity) following treatment, it should be easy to identify and then take six monthly IV infusions of cyclophosphamide that will be the finishing touch to the treatment. And of course you have a four-out-of-five chance the treatment will get it the first time.